东阳光药(06887)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06887 东阳光药

休市中 09-11 16:08:55

36.960

+0.380

+1.04%

最高36.980	最低35.980	成交量40.85万
今开36.000	昨收36.580	日振幅2.73%
总市值212.52亿	流通市值118.27亿	总股本5.75亿
成交额1,482万	换手率0.13%	流通股本3.20亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06887","market":"HK","secType":"STK","nameCN":"东阳光药","latestPrice":36.96,"timestamp":1789114135006,"preClose":36.58,"halted":0,"volume":408516,"delay":0,"changeRate":0.01038819026790603,"floatShares":320000000,"shares":575000000,"eps":0.55,"marketStatus":"休市中","change":0.38,"latestTime":"09-11 16:08:55","open":36,"high":36.98,"low":35.98,"amount":14818569,"amplitude":0.027337,"askPrice":36.98,"askSize":6900,"bidPrice":36.96,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.596326,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":7,"adr":0,"listingDate":1754496000000,"exchange":"SEHK","adjPreClose":36.58,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"volumeRatio":1.1959137360927483,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06887","defaultTab":"news","newsList":[{"id":"1117579240","title":"东阳光药更新2026年8月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1117579240","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117579240?lang=zh_cn&edition=full","pubTime":"2026-09-03 17:22","pubTimestamp":1788427330,"startTime":"0","endTime":"0","summary":"广东东阳光药业股份有限公司于2026年9月3日发布截至2026年8月31日止的股份变动月报表，报告期内公司股本情况未发生增加或减少，股本结构保持稳定。两类股份本月均无增减变动，月底合计注册股本仍为人民币576,656,047元。公告显示，当月无新增发行、回购、注销或其它股份变动活动。截至报告期末，东阳光药已符合适用的最低公众持股量要求。公司表示，将继续遵守香港联合交易所有限公司的相关上市规则和法律法规。本次月报由董事张英俊签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118789532","title":"东阳光药（06887）补充披露合伙基金主要条款及土地估值细节","url":"https://stock-news.laohu8.com/highlight/detail?id=1118789532","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118789532?lang=zh_cn&edition=full","pubTime":"2026-08-31 22:36","pubTimestamp":1788187001,"startTime":"0","endTime":"0","summary":"2026年8月31日，东阳光药发布补充公告，就6月26日公布的关联交易进一步披露设立合伙企业基金及收购土地使用权的相关信息。③ 如仍有剩余利润，20%计入普通合伙人绩效报酬，80%按出资比例分配。普通合伙人管理费：基金首个五年，每年按实缴出资总额0.5%计取；第二个五年，每年按已投资但未退出本金余额0.5%计取。除上述补充披露外，原公告其他内容保持不变。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663076609","title":"东阳光药发布2026年中期业绩：新旧动能切换，创新引擎接棒","url":"https://stock-news.laohu8.com/highlight/detail?id=2663076609","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663076609?lang=zh_cn&edition=full","pubTime":"2026-08-31 17:10","pubTimestamp":1788167406,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1191","06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182581873","title":"东阳光药2026年中期营收10.75亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1182581873","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182581873?lang=zh_cn&edition=full","pubTime":"2026-08-31 17:08","pubTimestamp":1788167304,"startTime":"0","endTime":"0","summary":"东阳光药发布截至二零二六年六月三十日止六个月财报，期内营收为10.75亿元，同比下降44.50%。毛利为5.78亿元，同比减少60.60%，毛利率约为53.78%，较上年同期的75.70%减少21.92个百分点。同期税息、折旧及摊销前亏损达到2.27亿元，而上年同期为盈利4.30亿元。公司核心业务主要分为抗感染、慢病治疗及其他产品三大板块，其中抗感染药物实现销售收入约5.82亿元，慢病治疗类产品实现销售收入约4.64亿元，其他产品销售收入约0.29亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"东阳光药2026年中期营收10.75亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663907654","title":"东阳光药(06887)发布中期业绩，收入10.75亿元 计划将强劲的营运现金流投入研发活动","url":"https://stock-news.laohu8.com/highlight/detail?id=2663907654","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663907654?lang=zh_cn&edition=full","pubTime":"2026-08-31 17:08","pubTimestamp":1788167301,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东阳光药 发布截至2026年6月30日止6个月中期业绩，该集团取得收入10.75亿元，毛利5.78亿元，公司权益股东应占亏损6.04亿元，每股亏损1.09元。公司计划将强劲的营运现金流投入研发活动，以大幅提升资金使用效率，为研发管线提供充足的支持。此外，公司将就此前的关连交易安排进行优化调整，提升决策及资金配置效率，降低治理成本。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489462.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4585","06887","BK1191","SPHQ","159399"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199543965","title":"东阳光药（06887）发布盈利警告：预计2026年上半年亏损约5.9亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1199543965","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199543965?lang=zh_cn&edition=full","pubTime":"2026-08-24 22:55","pubTimestamp":1787583352,"startTime":"0","endTime":"0","summary":"广东东阳光药业股份有限公司8月24日公告，根据集团目前可得的未经审核管理账目及管理层初步估算，截至2026年6月30日的六个月，公司预期录得归属公司权益持有人的亏损及全面收益总额约人民币5.9亿元。与2025年同期亏损及全面收益总额约人民币0.5亿元相比，亏损规模增加约人民币5.4亿元。东阳光药仍在编制截至2026年6月30日止六个月的中期业绩，相关中期业绩公告预计将于2026年8月31日刊发。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141461329","title":"东阳光药预计上半年亏损 主要因流感疫情缓解","url":"https://stock-news.laohu8.com/highlight/detail?id=1141461329","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141461329?lang=zh_cn&edition=full","pubTime":"2026-08-24 22:52","pubTimestamp":1787583160,"startTime":"0","endTime":"0","summary":"东阳光药日前发布公告，预计公司上半年将出现亏损。这一预期亏损主要归因于流感疫情在上半年有所缓和。\n随着流感病例数量的减少，公司相关产品的市场需求也随之下降，进而影响了整体的销售业绩和财务状况。在疫情缓解的大背景下，公司面临了较大的经营压力。\n分析人士指出，流感季节性的波动是影响公司业绩的关键因素之一。随着公共卫生状况的改善，抗病毒药物的需求自然回落，这直接反映在了公司的预期业绩上。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144508744","title":"东阳光药预计2026年上半年股东应占亏损达5.9亿元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=1144508744","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144508744?lang=zh_cn&edition=full","pubTime":"2026-08-24 22:51","pubTimestamp":1787583072,"startTime":"0","endTime":"0","summary":"东阳光药近日发布公告，预计截至2026年6月30日止六个月期间，公司股东应占亏损将达到人民币5.9亿元。这一财务预警揭示了公司在当前市场环境下面临的严峻挑战。该公司在公告中指出，预期亏损主要归因于多项经营及非经营性因素的叠加影响。在公告发布后，公司股票交易表现或将受到一定压力，但具体股价走势仍需视市场整体情绪及投资者对管理层指引的解读而定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187179793","title":"东阳光药（06887）将于8月31日审议2026年中期业绩及股息方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1187179793","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187179793?lang=zh_cn&edition=full","pubTime":"2026-08-19 16:37","pubTimestamp":1787128648,"startTime":"0","endTime":"0","summary":"广东东阳光药业股份有限公司（06887）19日公告称，董事会会议拟于2026年8月31日（星期一）召开，届时将审议并批准公司及其附属公司截至2026年6月30日止六个月的中期业绩，并考虑派发中期股息（如有）。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102118369","title":"东阳光药7月股份变动月报：总股本保持576,656,047股稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1102118369","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102118369?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:37","pubTimestamp":1785832656,"startTime":"0","endTime":"0","summary":"广东东阳光药业股份有限公司于2026年8月4日披露了截至2026年7月31日的股份变动月报表。报告期内，公司总股本保持不变，分别为H股321,103,140股和内资股255,552,907股，总数合计576,656,047股，面值均为人民币1元。根据公告，截至7月底，H股方面已发行股份由上月末的320,425,540股降至318,974,840股，相应的库存股由677,600股增至2,128,300股，增减数量均为1,450,700股；内资股则维持255,552,907股未发生改变。本次公告由董事张英俊签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656880065","title":"东阳光药遭张寓帅增持121.21万股 每股作价40.63港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2656880065","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656880065?lang=zh_cn&edition=full","pubTime":"2026-08-04 08:11","pubTimestamp":1785802260,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端香港联交所最新数据显示，7月31日，张寓帅增持东阳光药（06887）121.21万股，每股作价40.63港元，总金额约为4924.76万港元。增持后最新持股数目约为1.30亿股，持股比例为40.34%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-08-04/doc-inimcatv5481695.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["EWH","06887","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656346557","title":"东阳光药获股东张寓帅增持77.3万股 每股作价40.22港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2656346557","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656346557?lang=zh_cn&edition=full","pubTime":"2026-08-03 07:35","pubTimestamp":1785713700,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端香港联交所最新数据显示，7月30日，股东张寓帅增持东阳光药（06887）77.3万股，每股作价40.22港元，总金额约为3109.01万港元。增持后最新持股数目约为1.28亿股，持股比例为39.96%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-08-03/doc-inikytnx6211239.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["EWH","06887","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655694733","title":"东阳光药甘精胰岛素发运海外，商业化落地打开新空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2655694733","media":"经济参考网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655694733?lang=zh_cn&edition=full","pubTime":"2026-07-31 20:56","pubTimestamp":1785502599,"startTime":"0","endTime":"0","summary":"7月31日，东阳光药发布公告称其自主研发的甘精胰岛素注射液（商品名：Langlara）已启动美国市场商业化发货。首批计划发货总量为115.2万支，将分批次有序发货，预计于2026年8月中下旬完成。本次成品批量出货，为二级市场提供了可量化、可追踪的海外营收增量信号。这也是国内企业成功突破美国胰岛素市场的重要商业化案例。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607313828576573.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607313828576573.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06887","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181533841","title":"一周港股牛熊榜 | 海致科技周涨40%问鼎牛榜榜首；清盘人重启股权出售计划，恒大物业周涨23%；伟禄科技暴跌33%，遭大股东减持12%","url":"https://stock-news.laohu8.com/highlight/detail?id=1181533841","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181533841?lang=zh_cn&edition=full","pubTime":"2026-07-31 19:35","pubTimestamp":1785497713,"startTime":"0","endTime":"0","summary":"7月全月恒指累升3,003点或13.1%。该股7月21日盘中一度跌33%至111港元，此前7月17日尚报203.60港元。张先生通过其或透过其控制的实体计划于未来6个月增持价值介乎3.0亿港元至6.0亿港元的股份。下一步，计划邀请潜在买方对集团进行尽职调查。出售事项后，美林控股持有7.33亿股股份，占本公司已发行股本总额约50.83%。美林控股进一步告知董事会，据其深知、尽悉及确信，于出售事项前，买方为本公司及其关连人士的独立第三方","market":"hk","thumbnail":"https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02706","01783","02687","01196","06666","06166","06887","09606","09903","01888"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163476810","title":"东阳光药（06887）启动115.2万支甘精胰岛素首批对美商业化发货","url":"https://stock-news.laohu8.com/highlight/detail?id=1163476810","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163476810?lang=zh_cn&edition=full","pubTime":"2026-07-31 18:16","pubTimestamp":1785493012,"startTime":"0","endTime":"0","summary":"2026年7月31日，广东东阳光药业股份有限公司发布自愿性公告称，公司自主研发的甘精胰岛素注射液已正式启动美国市场商业化发货。首批计划发货总量为115.2万支，将分批有序发运，预计于2026年8月中下旬完成。甘精胰岛素为第三代长效胰岛素类似物，原研商品名为Lantus。根据公告，公司与美国合作方已签署不少于1,800万支产品订单，此次为该框架下的首批交付。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655357389","title":"东阳光药(06887.HK)：甘精胰岛素注射液首次美国商业化发货","url":"https://stock-news.laohu8.com/highlight/detail?id=2655357389","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655357389?lang=zh_cn&edition=full","pubTime":"2026-07-31 18:09","pubTimestamp":1785492592,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109049048","title":"张玉帅增持东阳光药150万股H股","url":"https://stock-news.laohu8.com/highlight/detail?id=1109049048","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109049048?lang=zh_cn&edition=full","pubTime":"2026-07-30 23:56","pubTimestamp":1785426998,"startTime":"0","endTime":"0","summary":"7月30日，东阳光药（06887.HK）披露，公司相关人士张玉帅于2026年7月24日至30日期间，累计购入150万股H股股份，总耗资约5600万港元。此次增持彰显了其对东阳光药未来发展的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655872466","title":"东阳光药德谷胰岛素获批上市，公司胰岛素产品增至6款","url":"https://stock-news.laohu8.com/highlight/detail?id=2655872466","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655872466?lang=zh_cn&edition=full","pubTime":"2026-07-30 20:10","pubTimestamp":1785413454,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["06887","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655740958","title":"东阳光药(06887)：德谷胰岛素注射液获得国家药品监督管理局(NMPA)的上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2655740958","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655740958?lang=zh_cn&edition=full","pubTime":"2026-07-30 19:59","pubTimestamp":1785412776,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东阳光药 发布公告，集团自主研发的德谷胰岛素注射液正式获得国家药品监督管理局批准上市，涵盖笔芯和预填充注射笔两个规格。在国际化方面，集团自主研发的甘精胰岛素注射液已于2026年4月底获得美国食品药品监督管理局签发的批准信，成为第4款在美国上市的甘精胰岛素产品，同时公司成为首个在美国市场上市甘精胰岛素的中国制药企业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474240.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","06887","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655587411","title":"股东张寓帅增持东阳光药(06887)37.75万股 每股作价38.40港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2655587411","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655587411?lang=zh_cn&edition=full","pubTime":"2026-07-30 19:45","pubTimestamp":1785411922,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，7月29日，股东张寓帅增持东阳光药(06887)37.75万股，每股作价38.40港元，总金额约为1449.60万港元。增持后最新持股数目约为1.28亿股，持股比例为39.72%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474226.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06887","BK1191","EWH"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0139},{"period":"1month","weight":0.0022},{"period":"3month","weight":0.067},{"period":"6month","weight":-0.1166},{"period":"1year","weight":-0.2933},{"period":"ytd","weight":-0.1895}],"compareEarnings":[{"period":"1week","weight":-0.033},{"period":"1month","weight":-0.0249},{"period":"3month","weight":0.0035},{"period":"6month","weight":-0.0259},{"period":"1year","weight":-0.0491},{"period":"ytd","weight":-0.0322}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"广东东阳光药业股份有限公司是一家主要从事药物的研发、生产和商业化的中国公司。该公司专注于创新药，亦涉及改良型新药、仿制药和生物类似药。该公司的抗感染产品包括可威（磷酸奥司他韦），用于治疗流行性感冒（特别是甲型及乙型流行性感冒病毒），东卫恩（磷酸依米他韦），用于治疗丙型肝炎，及主要用于治疗敏感细菌引起的感染的仿制药，即克拉霉素、左氧氟沙星及盐酸莫西沙星。该公司的慢病治疗药物主要专注于治疗糖尿病、高尿酸血症、高血压及胃酸相关疾病，包括胰岛素产品及仿制药。该公司还关注肿瘤治疗领域。","exchange":"SEHK","name":"东阳光药","nameEN":"SUNSHINE PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"东阳光药(06887)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供东阳光药(06887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"东阳光药,06887,东阳光药股票,东阳光药股票老虎,东阳光药股票老虎国际,东阳光药行情,东阳光药股票行情,东阳光药股价,东阳光药股市,东阳光药股票价格,东阳光药股票交易,东阳光药股票购买,东阳光药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"东阳光药(06887)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供东阳光药(06887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}